GlaxoSmithKline Plc

Source: www.topix.com --- 14 days ago
Zacks Analyst Blog Highlights: GlaxoSmithKline Plc., Metabasis Therapeutics, Inc., Central Garden & Pet Co., AFLAC Inc. ...

Source: www.topix.com --- 37 days ago
GlaxoSmithKline Plc today announced that Chris Viehbacher, Executive Director and President North American Pharmaceuticals, has decided to stand down from the Board on 8th September, and will leave the company ... ...

Source: salesandmarketingnetwork.com --- 24 days ago
Introduction This analysis examines the historical and forecast performance for GSK in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 ... Category: Company Profiles Published: 7-Aug-08 Pages: 139 ...

Source: www.alertdata.co.uk --- 38 days ago
Analyst: Move to bigger HQ will result in bigger profits Vindon Healthcare's move to a new site at Kingsway in Rochdale is expected to boost profit by almost 50 per cent by the end of next year, as the enlarged premises enable the company to branch out into... ...

Source: news.google.com --- 1 day ago
UPDATE 1-Glaxo expands in Egypt with $210 mln acquisition Reuters - 36 minutes ago LONDON, Oct 15 (Reuters) - GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research, Stock Buzz) is buying the Egyptian mature products business of Bristol-Myers Squibb Co (BMY. GlaxoSmithKline: $210 Million Egypt Business Buy From Bristol Myers CNNMoney.com Glaxo to pay $210 mln for Bristol-Myers Egypt unit MarketWatch RTT News all 137 news articles ...

Source: news.yahoo.com --- 34 days ago
Reuters - GlaxoSmithKline Plc's head of biotech research is excited about a new generation of "slimline" antibody medicines that may be successors to current blockbusters such as Avastin and Rituxan. ...

Source: timesofindia.indiatimes.com --- 33 days ago
GlaxoSmithKline Plc's head of biotech research is excited about a new generation of "slimline" antibody medicines that may be successors to current blockbusters such as Avastin and Rituxan. ...

Source: www.reuters.com --- 34 days ago
LONDON (Reuters) - GlaxoSmithKline Plc's head of biotech research is excited about a new generation of "slimline" antibody medicines that may be successors to current blockbusters such as Avastin and Rituxan. ...

Source: www.marketwatch.com --- 16 days ago
BOSTON (MarketWatch) -- Drug stocks slid into the red as global markets roiled in reaction to the U.S. banking crisis. The Amex Pharmaceutical Index dipped 1.1% to 296.07 and the Amex Biotechnology Index declined 0.9% to 796.98. Shares of major European pharmaceutical firms were the hardest hit, with AstraZeneca Plc , GlaxoSmithKline Plc , Novartis AG , Novo Nordisk A/S , Sanofi-Aventis and Shire Ltd. all trading down at least 2%. ...

Source: www.marketwatch.com --- 16 days ago
BOSTON (MarketWatch) -- Drug stocks were slammed in afternoon trading Monday following U.S. House of Representatives' largely unexpected rejection of legislation to aid the the ailing U.S. banking industry. The Amex Pharmaceutical Index and the Amex Biotechnology Index both fell about 5% to 283.24 and 765.95, respectively. Gilead Sciences and Celgene Corp. were the biggest losers on the large cap biotech side, both dropping at least 13%. On the Big Pharma side, European drugmakers GlaxoSmithKline Plc , Novo Nordisk A/S and Sanofi-Aventis were the sharpest decliners, all down over 6%. ...

Source: www.marketwire.com --- 20 days ago
GENEVA (MARKET WIRE) Addex Pharmaceuticals (SWISS: ADXN) announced today that on September 25, 2008, S.R. One Ltd, the investment arm of GlaxoSmithKline Plc, has informed of reaching the threshold of 3.0% in the shareholding of Addex Pharmaceuticals Ltd., holding a total of 175,951 registered shares, corresponding to 3.0% of the voting rights. ...

Source: clientportal.ibb.ubs.com --- 27 days ago
This document is related to the following: Regions Europe Including UK United Kingdom Global UBSW EMEA Companies BAES.L BAE SYSTEMS BARC.L Barclays BP.L BP RDSa.L Royal Dutch Shell RB.L Reckitt Benckiser REL.L Reed Elsevier Plc SSE.L Scottish & Southern SN.L Smith & Nephew VOD.L Vodafone Group XTA.L Xstrata Plc BG.L BG Group GSK.L GlaxoSmithKline ANTO.L Antofagasta AQP.L Aquarius Platinum ADML.L Admiral HOME.L Home Retail Group MNDI.L Mondi ...

Source: clientportal.ibb.ubs.com --- 20 days ago
This document is related to the following: Regions Europe Including UK United Kingdom Global UBSW EMEA Companies BAES.L BAE SYSTEMS BARC.L Barclays REX.L Rexam BP.L BP LLOY.L Lloyds TSB MRW.L Morrison (Wm.) RDSa.L Royal Dutch Shell RB.L Reckitt Benckiser REL.L Reed Elsevier Plc SSE.L Scottish & Southern SN.L Smith & Nephew VOD.L Vodafone Group XTA.L Xstrata Plc UBM.L UBM BG.L BG Group GSK.L GlaxoSmithKline ANTO.L Antofagasta ADML.L Admiral HOME.L Home Retail Group MNDI.L Mondi ...

Source: clientportal.ibb.ubs.com --- 39 days ago
This document is related to the following: Regions Europe Including UK United Kingdom Global UBSW EMEA Companies BAES.L BAE SYSTEMS BARC.L Barclays LLOY.L Lloyds TSB RB.L Reckitt Benckiser REL.L Reed Elsevier Plc SSE.L Scottish & Southern SN.L Smith & Nephew VOD.L Vodafone Group XTA.L Xstrata Plc BG.L BG Group GSK.L GlaxoSmithKline HBOS.L HBOS HOME.L Home Retail Group ...

Source: clientportal.ibb.ubs.com --- 35 days ago
This document is related to the following: Regions Europe Including UK Global Companies BAES.L BAE SYSTEMS BARC.L Barclays UHR.VX Swatch Group LING.DE Linde TOTF.PA TOTAL SGEF.PA Vinci ISP.MI Intesa SanPaolo REL.L Reed Elsevier Plc SSE.L Scottish & Southern VOD.L Vodafone Group XTA.L Xstrata Plc NOVN.VX Novartis BG.L BG Group KPN.AS KPN GSK.L GlaxoSmithKline EONGn.DE E.ON ...

Source: clientportal.ibb.ubs.com --- 34 days ago
This document is related to the following: Regions Europe Including UK United Kingdom Global UBSW EMEA Companies BAES.L BAE SYSTEMS BARC.L Barclays LLOY.L Lloyds TSB RB.L Reckitt Benckiser REL.L Reed Elsevier Plc SGC.L Stagecoach SSE.L Scottish & Southern SN.L Smith & Nephew VOD.L Vodafone Group XTA.L Xstrata Plc BG.L BG Group GSK.L GlaxoSmithKline AUTN.L Autonomy HBOS.L HBOS ISA.L Inmarsat HOME.L Home Retail Group FRES.L Fresnillo ...

Source: clientportal.ibb.ubs.com --- 13 days ago
This document is related to the following: Regions Europe Including UK United Kingdom Global UBSW EMEA Companies AMEC.L Amec UCB.BR UCB CBRY.L Cadbury ROG.VX Roche NESN.VX Nestlé BAYG.F Bayer DANO.PA Danone LMI.L Lonmin AKZO.AS Akzo Nobel ULVR.L Unilever Plc BULG.MI Bulgari XTA.L Xstrata Plc MRCG.DE Merck KGaA NOVN.VX Novartis ASSAb.ST Assa Abloy ACY.OL Acergy GSK.L GlaxoSmithKline VWS.CO Vestas GAM.MC Gamesa INTB.BR InBev TECF.PA Technip MKS.L Marks & Spencer PFC.L Petrofac AKSO.OL Aker Solutions SDRL.OL Seadrill EXPN.L Experian Group SUB.OL Subsea 7 FUGRc.AS Fugro TRIL.L Thomson Reuters Plc BUD.N Anheuser-Busch C.N Citigroup JPM.N JPMorgan Chase MS.N Morgan Stanley GS.N Goldman Sachs ICE.N ICE 8233.T Takashimaya Subjects Market Strategy / Comment Morning Note ...

Source: clientportal.ibb.ubs.com --- 37 days ago
This document is related to the following: Regions Europe Including UK Global Companies BAES.L BAE SYSTEMS BARC.L Barclays CFR.VX Richemont UHR.VX Swatch Group LING.DE Linde TOTF.PA TOTAL LAFP.PA Lafarge SGEF.PA Vinci ISP.MI Intesa SanPaolo REL.L Reed Elsevier Plc SSE.L Scottish & Southern VOD.L Vodafone Group XTA.L Xstrata Plc NOVN.VX Novartis BG.L BG Group KPN.AS KPN GSK.L GlaxoSmithKline EONGn.DE E.ON SUB.OL Subsea 7 Subjects Market Strategy / Comment Morning Note ...

Source: clientportal.ibb.ubs.com --- 37 days ago
This document is related to the following: Regions Europe Including UK United Kingdom Global UBSW EMEA Companies BAES.L BAE SYSTEMS BARC.L Barclays RB.L Reckitt Benckiser REL.L Reed Elsevier Plc SSE.L Scottish & Southern SN.L Smith & Nephew VOD.L Vodafone Group XTA.L Xstrata Plc BG.L BG Group GSK.L GlaxoSmithKline HOME.L Home Retail Group Subjects Market Strategy / Comment Morning Note ...

Source: www.drugs.com --- 1 day ago
LONDON, Oct. 15, 2008-GlaxoSmithKline Plc (GSK) today announced that it will acquire the Egyptian mature products business of Bristol Myers Squibb (BMS), for $210 (£125) million, in a move to accelerate sales growth and further extend its... ...